Advertisement: TTP Killer 50
19 February, 2022 - 13:34 By Tony Quested

Apollo Therapeutics

In 2021, portfolio-based biopharma venture Apollo Therapeutics announced it was  expanding its Cambridge UK and Boston US operations after raising $145 million growth capital. 

The proceeds will support rapid advancement of Apollo’s pipeline with more than 15 therapeutic programs currently in development across oncology, major inflammatory disorders and rare disease.

Newsletter Subscription

Stay informed of the latest news and features